| Name | Title | Contact Details |
|---|
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
Sage Recovery & Wellness Center Austin is an outpatient center specializing in both mental health and substance use, utilizing a holistic approach to recovery.
Zenabis is a significant Licensed Producer of medical and recreational cannabis, and employs staff coast-to-coast, across facilities in Atholville, New Brunswick; Delta and Langley, British Columbia; and Stellarton, Nova Scotia.
Spacelabs Healthcare is an American manufacturer of medical equipment and is a wholly owned subsidiary of OSI Systems of Hawthorne, California and offers products and services from three divisions: patient monitoring and connectivity, anesthesia delive...
Valensa International is a Eustis, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.